ERBB2 and breast cancer: Moreover, poly (ADP-ribose) polymerase inhibitors (PARPi) have received Food and Drug Administration (FDA) approval for the treatment of germline BRCA-mutated HER2-negative metastatic BC previously treated with chemotherapy in neoadjuvant, adjuvant, or metastatic settings.